FIELD: medicine; neurology.
SUBSTANCE: group of inventions discloses a pharmaceutical composition with neuromodulatory, antiparkinsonian, neuroprotective and antispastic effects, is intended for the treatment of cognitive impairment of vascular origin, slowing down and inhibiting glutamatergic neurotransmission and the progression of neurodegenerative processes, including memantine hydrochloride in the range values of 5–20 mg and citicoline monosodium salt in the range of 450–550 mg, with the following ratio of the quantitative and qualitative composition of the ingredients of the pharmaceutical composition, wt.%: 65.95–69.95 of citicoline monosodium salt; 0.67–2.50 of memantine hydrochloride; 0.63–5.13 of microcrystalline cellulose; 17.23–17.80 of hydroxypropyl methylcellulose (molecular weight 1,000,000); 0.91–1.0 of colloidal silicon dioxide; 0.91–1.0 of magnesium stearate; 3.00–7.00 of film shell I; 1.00–2.00 (options) of film shell II. Also the following is disclosed: solid oral dosage forms (options), methods of preparing a solid oral dosage form (options), medicinal products in the form of a modified-release tablet (options), use of a solid oral dosage form, and the use of a method.
EFFECT: increase in the therapeutic activity of citicoline, simplification of the treatment of cognitive disorders of vascular origin, reduction of side effects and the stability of dosage forms during manufacture and their stability during storage.
45 cl, 8 tbl
